• 1. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 2. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525

Introduction to 2-(2-aminoethyl)-1,2-thiazolidine-1,1-dione hydrochloride (CAS No. 1190044-24-6)

2-(2-aminoethyl)-1,2-thiazolidine-1,1-dione hydrochloride, identified by the Chemical Abstracts Service Number (CAS No.) 1190044-24-6, is a compound of significant interest in the field of pharmaceutical chemistry and medicinal research. This heterocyclic compound features a unique structural framework consisting of a thiazolidine ring system functionalized with an aminoethyl side chain and a dione moiety, further salted with hydrochloride. The molecular architecture of this compound imparts distinct chemical and biological properties, making it a valuable scaffold for the development of novel therapeutic agents.

The thiazolidine core is a six-membered saturated ring containing sulfur and oxygen atoms, which is known for its stability and versatility in drug design. The presence of the dione group enhances the electrophilic nature of the molecule, facilitating interactions with nucleophilic biological targets. Additionally, the aminoethyl substituent introduces basicity and potential for further derivatization, enabling the creation of diverse pharmacophores. These structural features collectively contribute to the compound's potential as an intermediate in synthesizing bioactive molecules.

In recent years, there has been growing interest in thiazolidine derivatives due to their broad spectrum of biological activities. Studies have demonstrated that compounds incorporating this motif exhibit properties such as antimicrobial, anti-inflammatory, and anticancer effects. The hydrochloride salt form of 2-(2-aminoethyl)-1,2-thiazolidine-1,1-dione hydrochloride enhances its solubility in aqueous media, which is crucial for formulation development and pharmacokinetic studies.

One of the most compelling aspects of this compound is its potential application in the field of enzyme inhibition. The dione group serves as a hydrogen bond acceptor, while the aminoethyl side chain can act as a hydrogen bond donor or participate in electrostatic interactions with protein targets. This dual functionality has been exploited in designing inhibitors targeting enzymes involved in metabolic pathways relevant to diseases such as diabetes and cancer. For instance, preliminary computational studies suggest that derivatives of this compound may interact with active sites of kinases and phosphodiesterases, modulating signaling pathways critical for cellular function.

Advances in synthetic methodologies have enabled more efficient preparation of complex thiazolidine derivatives. The synthesis of 2-(2-aminoethyl)-1,2-thiazolidine-1,1-dione hydrochloride involves multi-step reactions starting from commercially available precursors. Recent innovations in catalytic processes have improved yield and purity, reducing the need for extensive purification steps. This progress is particularly significant in drug discovery pipelines where scalability and cost-effectiveness are paramount.

The pharmacological evaluation of 2-(2-aminoethyl)-1,2-thiazolidine-1,1-dione hydrochloride has revealed promising results in preclinical models. In vitro assays have shown that certain derivatives exhibit inhibitory activity against enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are key mediators of inflammation. Furthermore, animal studies have indicated potential therapeutic effects in models of acute inflammation and pain syndromes. These findings underscore the compound's utility as a lead structure for developing novel anti-inflammatory agents.

The development of novel drug candidates requires rigorous assessment of their safety profiles before transitioning to clinical trials. Toxicological studies on 2-(2-aminoethyl)-1,2-thiazolidine-1,1-dione hydrochloride have focused on evaluating its acute toxicity, chronic exposure risks, and potential immunogenicity. Preliminary data suggest that the compound exhibits low toxicity at therapeutic doses but may require further investigation to identify any long-term adverse effects. Such assessments are essential for ensuring patient safety during subsequent phases of drug development.

The integration of computational chemistry into drug discovery has accelerated the identification of promising candidates like 2-(2-aminoethyl)-1,2-thiazolidine-1,1-dione hydrochloride. Molecular modeling techniques have been employed to predict binding affinities and optimize lead structures based on target enzyme interactions. These simulations provide valuable insights into how modifications to the molecular framework can enhance potency and selectivity without compromising solubility or pharmacokinetic properties.

The future prospects for 2-(2-aminoethyl)-1,2-thiazolidine-1,1-dione hydrochloride are promising given its versatile structural features and potential biological activities. Ongoing research aims to explore its efficacy in treating neurological disorders by targeting enzymes involved in neurodegenerative pathways. Additionally, efforts are underway to develop prodrugs that enhance bioavailability while maintaining therapeutic efficacy upon metabolic activation.

In conclusion, 2-(2-aminoethyl)-1,2-thiazolidine-1,1-dione hydrochloride (CAS No. 1190044-24-6) represents a significant advancement in pharmaceutical chemistry with broad applications across multiple therapeutic areas. Its unique structural attributes combined with recent advancements in synthetic biology position it as a valuable candidate for further exploration in drug development pipelines.

• 279669-65-7(2-Isopropylisothiazolidine 1,1-dioxide)
• 57547-95-2( )
• 73825-53-3(2-dodecyl-1,2-thiazolidine 1,1-dioxide)
• 83634-83-7(N-Methyl-1,3-propanesultam)
• 73343-04-1(2-Ethylisothiazolidine 1,1-dioxide)
• 1153064-58-4(2-(2-aminoethyl)-1lambda6,2-thiazolidine-1,1-dione)
• 505068-18-8(1-(propane-1-sulfonyl)piperazine)
• 114246-74-1(Isothiazolidine, 2-tetradecyl-, 1,1-dioxide)
• 505053-74-7(1-(ethylsulfonyl)-4-(propylsulfonyl)piperazine)
• 428504-12-5(1,4-bis(propylsulfonyl)piperazine)